Clinical Trial Update: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial (Phase 1) is evaluating the safety and potential efficacy of PRG-2311 for refractory lupus nephritis and IgG4-related disease and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease
• Lupus Nephritis

Drugs mentioned

• PRG-2311

Snippet

Sponsor: Tongji Hospital | Conditions: Lupus Nephritis, IgG4-related Disease | EARLY_Phase 1 | Status: RECRUITING